{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:54:12Z","timestamp":1782910452814,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003069","name":"Instituto Polit\u00e9cnico Nacional","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.arcmed.2020.01.013","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T17:45:21Z","timestamp":1582739121000},"page":"194-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["\u03b3\u03b4 T Cells Number, CD200, and Flt3 Expression Is Associated with Higher Progression Free Survival in Patients with Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"51","author":[{"given":"Rubiraida","family":"Molina-Aguilar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Arcelia","family":"Montiel-Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santa Victoria","family":"Anguiano-Pe\u00f1aloza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Lezama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Vela-Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elba","family":"Reyes-Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2020.01.013_bib1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.arcmed.2020.01.013_bib2","doi-asserted-by":"crossref","first-page":"30192","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12288-018-0933-1","article-title":"Laboratory monitoring of chronic myeloid leukemia in patients on tyrosine kinase inhibitors","volume":"34","author":"Chauhan","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.arcmed.2020.01.013_bib4","first-page":"179","article-title":"Molecular response in patients with chronic myeloid leukemia treated with imatinib\u2013single centre experience","volume":"36","author":"Pavkovic","year":"2015","journal-title":"Pril (Makedon Akad Nauk Umet Odd Med Nauki)"},{"key":"10.1016\/j.arcmed.2020.01.013_bib5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.4103\/ijmpo.ijmpo_115_17","article-title":"The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: Single-institutional experience over 13 years","volume":"38","author":"Chaitanya","year":"2017","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3332\/ecancer.2017.721","article-title":"Dual role of inflammatory mediators in cancer","volume":"11","author":"Shrihari","year":"2017","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.arcmed.2020.01.013_bib7","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2020.01.013_bib8","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppresion and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.arcmed.2020.01.013_bib9","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/25292","article-title":"Genetic instabilities in human cancers","volume":"396","author":"Lengauer","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.arcmed.2020.01.013_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1034\/j.1600-065X.2001.1820102.x","article-title":"Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance","volume":"182","author":"Sakaguchi","year":"2001","journal-title":"Immunol Rev"},{"key":"10.1016\/j.arcmed.2020.01.013_bib12","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/ni1102-999","article-title":"Natural selection of tumor variants in the generation of \u201cTumor Scape\u201d Phenotypes","volume":"3","author":"Khong","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.arcmed.2020.01.013_bib14","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.arcmed.2020.01.013_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1034\/j.1600-0897.2003.00086.x","article-title":"Placental Trophoblast from successful human pregnancies expresses the tolerance signaling molecule, CD200 (OX-2)","volume":"50","author":"Clark","year":"2003","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib16","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1182\/blood-2006-06-029355","article-title":"CD200 is a new prognostic factor in multiple myeloma","volume":"108","author":"Moreaux","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2020.01.013_bib17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.leu.2404559","article-title":"CD200 as a prognostic factor in acute myeloid leukaemia","volume":"21","author":"Tonks","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.arcmed.2020.01.013_bib18","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.4049\/jimmunol.178.9.5595","article-title":"CD200 expresion on tumor cells supresses antitumor immunity: new approaches to cancer immunotherapy","volume":"178","author":"Kretz-Rommel","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.leukres.2008.08.021","article-title":"Disruption of T cell suppression in chronic lymphoeytic leukemia by CD200 blockade","volume":"33","author":"Pallasch","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.arcmed.2020.01.013_bib20","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.4049\/jimmunol.171.6.3034","article-title":"Characterizacion of the CD200 receptor family in mice and humans and their interaction with CD200","volume":"171","author":"Wright","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.coi.2012.01.002","article-title":"CD200R signaling in tumor tolerance and inflammation: a tricky balance","volume":"24","author":"Rygiel","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib22","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.V82.4.1110.1110","article-title":"Human FLT3\/FLK2 gene: cDNA cloning and expression in hematopoietic cells","volume":"82","author":"Rosnet","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2020.01.013_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2007.06525.x","article-title":"FLT3\/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem\/progenitor cells","volume":"137","author":"Li","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V100.1.59","article-title":"Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study usefulness as a marker for the detection of minimal residual disease","volume":"100","author":"Schnittger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2020.01.013_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.clml.2018.05.014","article-title":"Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients","volume":"18","author":"Kandeel","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.arcmed.2020.01.013_bib26","doi-asserted-by":"crossref","first-page":"5689464","DOI":"10.1155\/2019\/5689464","article-title":"Interaction of CD200 Overexpression on Tumor Cells with CD200R1 Overexpression on Stromal Cells: An Escape from the Host Immune Response in Rectal Cancer Patients","volume":"2019","author":"Bisgin","year":"2019","journal-title":"J Oncol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib27","first-page":"937","article-title":"Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia","volume":"10","author":"List","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.arcmed.2020.01.013_bib28","doi-asserted-by":"crossref","first-page":"172655","DOI":"10.1016\/j.ejphar.2019.172655","article-title":"Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy","volume":"5","author":"Suvarna","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib29","doi-asserted-by":"crossref","first-page":"32259","DOI":"10.1074\/jbc.M111.278127","article-title":"Allyl isothiocyanate arrests cancer cells in mitosis, and mitotic arrest in turn leads to apoptosis via Bcl-2 protein phosphorylation","volume":"286","author":"Geng","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.arcmed.2020.01.013_bib30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s12185-013-1334-8","article-title":"FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechamisms of resistance","volume":"97","author":"Grumwald","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drup.2008.12.001","article-title":"Mechanisms of resistance to FLT3 innibitors","volume":"12","author":"Chu","year":"2009","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.arcmed.2020.01.013_bib32","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/sj.bjc.6603599","article-title":"Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction","volume":"96","author":"Lickliter","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.arcmed.2020.01.013_bib33","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.celrep.2016.10.086","article-title":"Tailored tumor immunogenicity reveals regulation of CD4 and CD8 T cell responses against cancer","volume":"17","author":"Knocke","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.arcmed.2020.01.013_bib34","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00262-017-2040-9","article-title":"Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy","volume":"66","author":"Sander","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.arcmed.2020.01.013_bib35","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study","volume":"2","author":"Mussini","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.arcmed.2020.01.013_bib36","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/10428190500051893","article-title":"Anti-lymphoma effect of \u03b3\u03b4 T cells","volume":"46","author":"Kunzmann","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.arcmed.2020.01.013_bib37","first-page":"438443","article-title":"CD200 protein, bad prognostic in patients with multiple myeloma","volume":"53","author":"Vela-Ojeda","year":"2015","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"10.1016\/j.arcmed.2020.01.013_bib38","doi-asserted-by":"crossref","first-page":"13551","DOI":"10.18632\/oncotarget.6948","article-title":"Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia","volume":"7","author":"Miao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.arcmed.2020.01.013_bib39","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/leu.2012.77","article-title":"Expression of CD200 on AML blasts directly suppresses memory T-cell function","volume":"26","author":"Coles","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.arcmed.2020.01.013_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40425-014-0046-9","article-title":"CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy","volume":"2","author":"Moertel","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.arcmed.2020.01.013_bib41","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-16-2353","article-title":"Disease characteristics and prognostic implications of cell-surface FLT3 receptor (CD135) expression in pediatric acute myeloid leukemia: a report from the children\u2019s oncology group","volume":"23","author":"Tarlock","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2020.01.013_bib42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/molecules23010119","article-title":"Towards comprehension of the ABCB1\/P-Glycoprotein role in chronic myeloid leukemia","volume":"23","author":"Maia","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.arcmed.2020.01.013_bib43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.arcmed.2018.04.006","article-title":"Prognostic value of CD95, active caspase-3, and Bcl-2 expression in adult patients with de novo acute lymphoblastic leukemia","volume":"49","author":"Montiel-Cervantes","year":"2018","journal-title":"Arch Med Res"},{"key":"10.1016\/j.arcmed.2020.01.013_bib44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","article-title":"BCL-2 as therapeutic target for hematological malignancies","volume":"11","author":"Perini","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24096","article-title":"Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib46","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.6004\/jnccn.2016.0162","article-title":"NCCN guidelines insights: chronic myeloid leukemia, version 1.2017","volume":"14","author":"Pallera","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.arcmed.2020.01.013_bib47","first-page":"11","article-title":"Targeting BCL-2 in hematologic malignancies","volume":"1","author":"Khan","year":"2018","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.arcmed.2020.01.013_bib48","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.18632\/oncotarget.23691","article-title":"Prognostic factors associated with a stable MR 4.5 achievement in chronic myeloid leukemia patients treated with imatinib","volume":"9","author":"Breccia","year":"2018","journal-title":"Oncotarget"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440918305162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440918305162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:48:29Z","timestamp":1759261709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440918305162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0188440918305162"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.01.013","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b3\u03b4 T Cells Number, CD200, and Flt3 Expression Is Associated with Higher Progression Free Survival in Patients with Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 IMSS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}